Syncona, a healthcare company, completed the acquisition of Applied Genetic Technologies, a clinical-stage biotechnology company focused on the development and commercialisation of adeno-associated virus based gene therapies, for $73m. "Our team has completed ground-breaking work for patients living with devastating retinal diseases. This transaction allows continued progress in advancing an important therapy for XLRP patients while also maximizing immediate and potential long-term value to our shareholders. On closing, AGTC will be Syncona's third company focused on retinal gene therapy, and we look forward to transitioning the AGTC-501 XLRP product candidate to Syncona's experienced stewardship with the goal of advancing this differentiated product candidate to patients," Sue Washer, AGTC President and CEO.